Aeglea BioTherapeutics, Inc. (AGLE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
805 Las Cimas Parkway
Austin, TX 78746
United States of America (the)
Phone
512 942 2935
Website
Sector
Healthcare
Industry
Biotechnology
Employees
69
First IPO Date
April 07, 2016
| Name | Title | Pay | Year Born |
| Cameron Turtle | Chief Operating Officer & Principal Executive Officer | 0 | 1990 |
| Scott L. Burrows | Chief Financial Officer | 0 | 1977 |
| Kelly Boothe | Senior Director of Corporation Communications & Investor Relations | 0 | N/A |
| Joey Perrone | Vice President of Finance & Investor Relations | 0 | N/A |
| Heidy Abreu King-Jones | Chief Legal Officer & Corporate Secretary | 0 | 1983 |
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.